BaroFold Inc.

BaroFold Inc. is a biotechnology company that specializes in advanced pressure-based technologies for biological sample preparation, enhancing the effectiveness and solubility of complex compounds. BaroFold Inc. focuses on developing innovative solutions for the life sciences sector.

Founded in Aurora, US, the company raised USD 9. 60 mn in Series A funding on May 24, 2007, led by Boulder Ventures, HBM Partners, and Peierls Foundation. The company has undergone no major pivots or changes in its business operations since its inception. BaroFold Inc.

offers advanced pressure-based technologies aimed at the life sciences industry. Its flagship products include the BaroShear™ K45, which creates high-quality, water-soluble nanoemulsions of CBD oil, and the Barocycler 2320EXT, designed for simultaneous processing of multiple samples using PCT MicroTubes. These instruments cater to research institutions and pharmaceutical companies globally, particularly in North America, Europe, and Asia. BaroFold Inc.

generates revenue through the sale of its proprietary instruments and contract services, particularly high-pressure protein refolding technology under its Barofold™ brand. It engages in direct sales to B2B clients, including universities and research facilities, and partners with commercial entities for specialized applications to diversify its revenue streams. Following the Series A financing of USD 9. 60 mn raised in May 2007, BaroFold Inc.

plans to utilize these funds to expand its product development and enhance market reach. The company is working on launching new products designed for biological applications, with specific release dates to be announced as they approach. Additionally, BaroFold aims to target new markets and geographic regions, particularly in Europe and Asia, by the end of 2024.